Ligand Pharmaceuticals (LGND) Loans and Notes Receivables (2015 - 2018)

Ligand Pharmaceuticals' Loans and Notes Receivables history runs 4 years deep, the most recent figure standing at $3.9 million for Q1 2018.

• In Q1 2018, Loans and Notes Receivables changed N/A year-over-year to $3.9 million; the TTM figure through Mar 2018 stood at $3.9 million (changed N/A YoY), while the FY2017 annual figure was $3.9 million, up 20.89% from the prior year.
• Loans and Notes Receivables came in at $3.9 million for Q1 2018 at Ligand Pharmaceuticals, roughly flat from $3.9 million in the prior quarter.
• In the past five years, Loans and Notes Receivables ranged from a high of $5.5 million in Q2 2015 to a low of $3.0 million in Q3 2017.
• A 4-year average of $4.1 million and a median of $3.9 million in 2017 frame the typical range for Loans and Notes Receivables.
• Across the five-year window, Loans and Notes Receivables tumbled 42.18% in 2016 and gained 20.89% in 2017, its largest moves.
• Ligand Pharmaceuticals' Loans and Notes Receivables stood at $4.8 million in 2015, then sank by 32.94% to $3.2 million in 2016, then increased by 20.89% to $3.9 million in 2017, then changed by 0.0% to $3.9 million in 2018.
• According to Business Quant data, Loans and Notes Receivables over the past three periods registered $3.9 million, $3.9 million, and $3.0 million for Q1 2018, Q4 2017, and Q3 2017 respectively.

Peer Comparison